Cite
MLA Citation
Won‐Mook Choi et al.. “Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma.” Hepatology communications, vol. 4, no. 7, 2020, pp. 1073–1086. http://access.bl.uk/ark:/81055/vdc_100103800873.0x000003